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Methodology: 
8 patients with prostate cancer were treated in the radiotherapy 
department of Cliniques Universitaires Saint-Luc – Brussels. 
Patients age is between 60 and 83 years old, with an average of 72 
(sd=8,5). In table 1 we can see the sample characterization. 
Table 1 – Sample characterization. 
 
 
 
 
 
 
 
 
Planning Process 
All patients underwent a computerized tomography (CT) with a 
contrast and rectal probe. They were placed in supine position with 
the hands on the chest, a leg and feet support and a pillow under 
the head. The patients drank 500ml of water with 10cc of 
Gastrografin® one hour and half before the CT. Then the images 
were acquired and sent to the Focal® system. Here the rectum, 
head of femur, bladder, CTV 1 and 2 were  delimited in all slices and 
after the images were sent to the treatment planning system (TPS). 
In the CTV 1 we include the prostate and seminal vesicles and the 
CTV 2 consist only in the prostate. The PTV 1 and 2 were created in 
the TPS with a margin of 7mm relative to the corresponding CTV. 
For all patients it was prescribed 74 to 78Gy with 2Gy per fraction. 
3DCRT 
The 3DCRT plans were created trough XiO® TPS, version 4.40.00. 
There were performed 5 to 7 fields with 18MV and for optimization 
was used wedges, different field weights, gantry rotations, multi-leaf 
collimators and field-in-field technique. 
Tomotherapy 
The TH plans were created trough Hi-Art Helical Tomotherapy®. 
For all plans it was used a jaw width of 2.5cm, a pitch of 0,287 
and a modulation factor <2. 
Statistical Analysis 
The data was analysed by the Statistical Package for Social 
Sciences (SPSS), 20. It was used the Wilcoxon test to compare 
all parameters of the two techniques (ρ≤0,05). 
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Final Considerations: 
With this study we observed a significant dose reduction  in the heads of 
femur, when TH is applied. Also we can find in the data a slight 
improvement in the homogeneity  of the dose with TH, when compared 
to the 3DCRT. In future studies it could be possible to assess the dose in 
PTV and OAR with TH and volumetric modulated arc therapy. 
 
Introduction: 
Radiotherapy is one of the therapeutics selected for localized 
prostate cancer, in cases where the tumour is confined to the 
prostate, penetrates the prostatic capsule or has reached the 
seminal vesicles (T1 to T3 stages)1. The radiation therapy can be 
administered through  various modalities, being historically used the 
3D conformal radiotherapy (3DCRT)2-4. Other modality of radiation 
administration is the intensity modulated radiotherapy (IMRT), that 
allows an increase of the total dose through modulation of the 
treatment beams, enabling a reduction in toxicity2-6. One way to 
administer IMRT is through helical tomotherapy (TH)7-8. 
With this study we intent to analyze the advantages of helical 
tomotherapy when compared with 3DCRT, by evaluating the doses 
in the organs at risk (OAR) and planning target volumes (PTV). 
Patient Volume (cc) TNM 
PTV 1 PTV 2 
1 216,45 123,28 T3a N0 M0 
2 182,40 124,67 T1c N0 M0 
3 190,89 141,71 T2 N0 M0 
4 150,99 84,78 T2a N0 M0 
5 182,10 111,76 T2 N0 M0 
6 168,31 77,00 T3 N0 M0 
7 216,33 106,19 T2a N0 M0 
8 193,45 139,15 T1c N0 M0 
Results: 
In table 2 we observed the dose average in the PTV and OAR. 
Table 2 – Average values of the dose in PTV and OAR.  
3DCRT TH ρ 
Rectum 
Maximum Dose (%) 99.95 (
 
1.57) 104.05 (
 
0.78) .012* 
Average Dose (%) 54.58 (
 
11.74) 41.97 (
 
15.92) .012* 
Minimum Dose 4.07(
 
5.25) 5.50 (
 
4.21) .123 
V50% 51.26 (
 
21.87) 42.89 (
 
12.17) .093 
V25% 78.17 (
 
6.89) 63.66 (
 
17.55) .069 
Right Head Femur 
Maximum Dose (%) 65.02 (
 
4.98) 44.01 (
 
4.91) .012* 
Average Dose (%) 47.62 (
 
8.88) 23.73 (
 
5.07) .012* 
Minimum Dose 3.51 (
 
1.91) 9.82 (
 
5.07) .012* 
V50% 54.66 (
 
7.52) 23.08 (
 
4.97) .012* 
Left Head Femur 
Maximum Dose (%) 64.98 (
 
6.90) 43.42 (
 
4.79) .012* 
Average Dose (%) 46.46 (
 
9.32) 23.27 (
 
5.25) .012* 
Minimum Dose 3.26 (
 
1.73) 9.71 (
 
4.70) .012* 
V50% 55.40 (
 
7.03) 23.14 (
 
4.92) .012* 
Bladder 
Maximum Dose (%) 99.70 (
 
2.10) 103.56 (
 
2.21) .017* 
Average Dose (%) 36.13 (
 
16.39) 33.43 (
 
14.12) .575 
Minimum Dose 5.04 (
 
11.94) 4.18 (
 
5.73) .161 
V50% 25.28 (
 
24.58) 28.34 (
 
16.76) .401 
V25% 56.64 (
 
21.46) 59.45 (
 
15.67) .779 
PTV1 
Maximum Dose (%) 103.13 (
 
3.62) 105.70 (
 
.90) .069 
Average Dose (%) 99.97 (
 
2.86) 100.00 (
 
.23) .889 
Minimum Dose 92.76 (
 
1.78) 85.65 (
 
3.69) .012* 
V95% 97.33 (
 
2.56) 96.69 (
 
.57) .263 
PTV2 
Maximum Dose (%) 100.86 (
 
1.81) 105.65 (
 
.66) .012* 
Average Dose (%) 98.78 (
 
1.99) 100.01 (
 
.17) .093 
Minimum Dose 92.78 (
 
1.70) 86.21 (
 
3.83) .025* 
V95% 97.01 (
 
1.66) 96.83 (
 
.52) .779 
